R&G PharmaStudies Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020
Revenue	789.45	744	721.37	637.52	608.43	484.45
Revenue Growth (YoY)	4.06%	3.14%	13.15%	4.78%	25.59%	13.87%
Cost of Revenue	517.47	468.08	434.34	402.62	375.25	294.29
Gross Profit	271.98	275.92	287.04	234.9	233.17	190.16
Selling, General & Admin	66.55	91.29	94.45	75.34	71.85	60.26
Research & Development	60.4	56.83	52.86	49.99	41.19	34.7
Other Operating Expenses	5.5	3.39	3.76	3.01	3.43	2.26
Operating Expenses	135.9	154.88	155.93	131.92	124.02	102.31
Operating Income	136.07	121.05	131.11	102.98	109.15	87.85
Interest Expense	-3.09	-3.44	-0.6	-0.67	-0.58	-
Interest & Investment Income	21.5	23.17	34.6	15.04	5.46	4.04
Currency Exchange Gain (Loss)	1.72	1.72	1.38	5.73	-1.34	-3.39
Other Non Operating Income (Expenses)	-2.2	-1.79	-0.35	-0.58	-0.41	-0.34
EBT Excluding Unusual Items	154.01	140.7	166.14	122.5	112.28	88.16
Gain (Loss) on Sale of Investments	8.92	11.28	3.98	0.91	-2.1	-
Gain (Loss) on Sale of Assets	-0.01	-0.07	-0.02	-0.02	-0.02	-0
Asset Writedown	0.17	-	-	-	-	-0.04
Other Unusual Items	7.31	5.87	12.37	5.5	3.44	8.37
Pretax Income	170.4	157.79	182.47	128.89	113.6	96.48
Income Tax Expense	17.67	16	19.61	14.75	13.24	11.19
Earnings From Continuing Operations	152.73	141.79	162.86	114.13	100.35	85.29
Minority Interest in Earnings	-1.36	-1.57	-0.33	-0.69	-1.12	-1.45
Net Income	151.37	140.22	162.53	113.45	99.24	83.84
Net Income to Common	151.37	140.22	162.53	113.45	99.24	83.84
Net Income Growth	25.00%	-13.73%	43.27%	14.32%	18.37%	1.46%
Shares Outstanding (Basic)	95	95	96	82	72	72
Shares Outstanding (Diluted)	95	95	96	82	72	72
Shares Change (YoY)	-0.87%	-0.64%	16.78%	14.43%	-0.38%	0.37%
EPS (Basic)	1.59	1.47	1.69	1.38	1.38	1.16
EPS (Diluted)	1.59	1.47	1.69	1.38	1.38	1.16
EPS Growth	26.10%	-13.17%	22.68%	-0.09%	18.82%	1.09%
Free Cash Flow	59.76	134.78	172.68	109.64	76.29	18.62
Free Cash Flow Per Share	0.63	1.41	1.80	1.33	1.06	0.26
Dividend Per Share	0.160	0.160	0.200	0.156	-	-
Dividend Growth	-20.00%	-20.00%	27.96%	-	-	-
Gross Margin	34.45%	37.09%	39.79%	36.85%	38.32%	39.25%
Operating Margin	17.24%	16.27%	18.18%	16.15%	17.94%	18.13%
Profit Margin	19.17%	18.85%	22.53%	17.79%	16.31%	17.31%
Free Cash Flow Margin	7.57%	18.12%	23.94%	17.20%	12.54%	3.84%
EBITDA	132.68	128.8	153.73	110.43	135.31	94.32
EBITDA Margin	16.81%	17.31%	21.31%	17.32%	22.24%	19.47%
D&A For EBITDA	-3.39	7.75	22.62	7.44	26.16	6.47
EBIT	136.07	121.05	131.11	102.98	109.15	87.85
EBIT Margin	17.24%	16.27%	18.18%	16.15%	17.94%	18.13%
Effective Tax Rate	10.37%	10.14%	10.75%	11.45%	11.66%	11.60%
Revenue as Reported	789.45	744	721.37	637.52	608.43	-
Advertising Expenses	-	-	-	-	1.61	3.09

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.